Last reviewed 2026-04-20 · How we verify

5-Isopropyldeoxyuridine (EPERVUDINE)

Phase 2 active Small molecule

5-Isopropyldeoxyuridine (generic name: EPERVUDINE) is a epervudine drug. It is currently in Phase 2 development.

EPERVUDINE works by inhibiting viral replication, specifically targeting the viral DNA polymerase.

EPERVUDINE, also known as 5-Isopropyldeoxyuridine, is a small molecule drug in the epervudine class. Its exact target is unknown, but it is believed to work by inhibiting viral replication. EPERVUDINE has not been approved by the FDA for any indications. The commercial status of EPERVUDINE is unclear, with no information available on generic manufacturers or patent status. Further research is needed to determine the safety and efficacy of this compound.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EPERVUDINE
Drug class	epervudine
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of EPERVUDINE like a roadblock for the virus. It prevents the virus from making copies of itself by blocking the enzyme that helps the virus replicate its genetic material. This can help slow down the spread of the virus in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

5-Isopropyldeoxyuridine CI brief — competitive landscape report
5-Isopropyldeoxyuridine updates RSS · CI watch RSS

Frequently asked questions about 5-Isopropyldeoxyuridine

What is 5-Isopropyldeoxyuridine?

5-Isopropyldeoxyuridine (EPERVUDINE) is a epervudine drug.

How does 5-Isopropyldeoxyuridine work?

EPERVUDINE works by inhibiting viral replication, specifically targeting the viral DNA polymerase.

What is the generic name of 5-Isopropyldeoxyuridine?

EPERVUDINE is the generic (nonproprietary) name of 5-Isopropyldeoxyuridine.

What drug class is 5-Isopropyldeoxyuridine in?

5-Isopropyldeoxyuridine belongs to the epervudine class. See all epervudine drugs at /class/epervudine.

What development phase is 5-Isopropyldeoxyuridine in?

5-Isopropyldeoxyuridine is in Phase 2.

Drug class: All epervudine drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing